Paydirt
AS
Insider

Alvin Shih

Director

Alvin Shih (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Zevra Therapeutics, Inc. (ZVRA). Across 1 priced purchase filing, the average 21-session return was +39.0% from execution and +38.3% from disclosure (delay-adjusted; derived). The largest single filing was $158K of ZVRA (20,000 sh × $7.89, as filed), executed Sep 12 2025.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
+39.0%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+38.3%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$158K
shares × price, as filed
Last traded
Sep 12 2025
Filed Sep 15 2025

Median ADV $19.3M across their filed names

Open performance
Volume by month
$158K$79K$0Oct 2024Apr 2025Oct 2025Apr 2026Sep 2025 · buys $158K
Buys $158K Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 1 filing

Sector per market data · by filing · past 24 months

Most traded names
ZVRA Zevra Therapeutics, Inc. ZVRA · 1 buy · 0 sells 1 filing
Recent filings
ZVRAPURCHASE Zevra Therapeutics, Inc. View filing → $158K
20,000 sh × $7.89
Exec Sep 12 2025
Filed Sep 15 2025 · 4:07 PM ET